DENVER & LOS ALTOS, Calif.--(BUSINESS WIRE)--TOPICA Pharmaceuticals, Inc., a privately held biotechnology company, today announced interim safety and mycologic susceptibility results from the ongoing Phase 2b/3 SOLUTION Study evaluating 10% Luliconazole Solution. With 334 patients enrolled in the clinical trial and approximately 50 patients having completed the study’s protocol at week 52, Luliconazole Solution is very well tolerated topically and shows no signs of systemic side effects at this point in the trial.
Help employers find you! Check out all the jobs and post your resume.
